民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2023年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所上市公司自律监管指引第11号——持续督导》 等有关法律、法规的规定，民生证券股份有限公司（以下简称"民生证券" 或"保荐机构"）作为杭州安旭生物科技股份有限公司（以下简称"安旭生 物"或"公司"）持续督导工作的保荐机构，负责安旭生物上市后的持续督导 工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 | 序号 | 工作情况 | 持续督导情况 | | --- | --- | --- | | 1 | | 保荐机构已建立健全并有效执 行了持续督导制度，并制定了相 | | | 建立健全并有效执行持续督导工作制度，并针对 | | | | 具体的持续督导工作制定相应的工作计划 | 应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始 | 保荐机构已与安旭生物签订《保 | | | 前，与上市公司或相关当事人签署持续督导协 | 荐协议》，该协议明确了双方在 | | | 议，明确双方在持续督导期间的权利义务，并报 | 持续 ...

2023 年半年度报告 公司代码: 688075 公司简称：安旭生物 杭州安旭生物科技股份有限公司 2023 年半年度报告 syre Toch 安旭生物 1 / 155 2023 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"五、风险因素"中说明了可能对公司产生重 大不利影响的风险因素，敬请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、经营计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意投资风险。 九、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 十、 是否存在违反规定决策程序对外提供担保的情况？ 否 十一、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十二、 其他 □适用 √不适用 2 ...

Corporate Structure and Management - The company has 13 first-level subsidiaries and 3 second-level subsidiaries, all managed under a centralized group management system[2] - The company's internal control system was deemed effective by the audit firm ShineWing, with no significant deficiencies reported[3] - The company has established a flat management structure to facilitate communication and feedback between employees and management[23] - The company elected Dong Wenkun and Huang Yinqian as non-independent directors for the second board of directors[109] - The company elected Zhang Guobiao, Zhou Juanying, and Ma Weimin as independent directors for the second board of directors[109] - The company elected Hong Yuyan and Zhou Lala as non-employee representative supervisors for the second board of supervisors[109] - Ling Shisheng, Chairman and CEO, holds 22,806,800 shares at the end of the year, an increase of 7,396,800 shares due to equity distribution[111] - Jiang Xueying, Vice Chairman and Deputy General Manager, holds 1,817,736 shares at the end of the year, an increase of 589,536 shares due to equity distribution[111] - The total number of shares held by directors, supervisors, and senior management increased by 7,986,336 shares to 24,624,536 shares at the end of the year[114] - Ling Shisheng has been the Chairman and CEO since August 2019, with extensive experience in the biotech industry[114] - Jiang Xueying has been the Vice Chairman and Deputy General Manager since April 2022, with a background in law and corporate management[114] - Dong Wenkun has been the Director, Deputy General Manager, and R&D Director since August 2019, with a strong background in biotech R&D[114] - Huang Yinqian has been the Director and Production Operations Director since August 2019, with experience in quality management and production operations[114] - Wu Yahong stepped down as CFO on December 26, 2022, but continued as Board Secretary until March 6, 2023, when Han Jun was appointed as the new Board Secretary[116][117] - Kang Min was appointed as CFO on December 26, 2022, following Wu Yahong's resignation[116] Environmental and Social Responsibility - The company invested 1.0225 million RMB in environmental protection during the reporting period[5] - The company did not directly emit greenhouse gases but consumed electricity, falling under the category of equivalent greenhouse gas emissions[8] - The company's main energy consumption includes water, electricity, and natural gas, supplied by local authorities[9] - The company reduced carbon emissions by implementing low-carbon measures in office operations, R&D, and future production base construction[13] - The company donated 849,100 RMB in cash and 5.7387 million RMB in materials for public welfare activities, including donations to educational foundations and the 2022 Asian Games Organizing Committee[14] - The company contributed 50,000 RMB to rural revitalization efforts, specifically donating to Anji County Fourth Primary School[17] - The company strictly adheres to environmental laws and regulations, ensuring compliance with emission standards and waste management[12] - The company actively participated in social responsibility initiatives, including poverty alleviation and rural revitalization projects[17] - The company donated antigen products to multiple regions and institutions, including Hangzhou Shangcheng District, Changchun City in Jilin Province, and Hong Kong, and has been awarded the title of "Love Enterprise" by the Red Cross Society of Shangcheng District, Hangzhou[153] Financial Performance and Dividends - The company plans to distribute a cash dividend of 50 yuan per 10 shares, totaling 453,867,160.00 yuan (including tax), accounting for 14.91% of the net profit attributable to shareholders in 2022[29] - The company intends to increase its share capital by 4 shares per 10 shares through capital reserve, resulting in a total share capital increase to 127,082,805 shares[29] - The company's full-year revenue for 2022 reached RMB 3.45 billion, representing a year-over-year growth of 28.5%[35] - Net profit for 2022 was RMB 1.23 billion, an increase of 35.2% compared to the previous year[35] - The company's gross margin improved to 65.8% in 2022, up from 62.3% in 2021[35] - Revenue in 2022 increased by 287.97% year-on-year to RMB 6,165,884,330.92, driven by market recognition of the company's high-quality testing products and expanded sales scale[43][44] - Net profit attributable to shareholders of the listed company surged by 312.26% year-on-year to RMB 3,044,673,309.82, in line with the significant revenue growth[43][44] - Net cash flow from operating activities rose by 453.79% year-on-year to RMB 3,743,278,071.62, primarily due to increased revenue and corresponding collections[43][44] - Shareholders' equity attributable to the listed company grew by 108.02% year-on-year to RMB 5,421,936,037.32, mainly due to increased retained earnings from profitability[43][48] - Total assets increased by 111.61% year-on-year to RMB 6,941,682,206.33, driven by higher asset investments and improved sales collections[43][48] - Basic earnings per share (EPS) and diluted EPS both increased by 217.91% year-on-year to RMB 33.54, reflecting higher profitability[43][48] - Revenue for 2022 reached 61.66 billion yuan, a year-on-year increase of 287.97%[56] - Net profit attributable to the parent company was 30.45 billion yuan, up 312.26% year-on-year[56] - Total assets at the end of 2022 were 69.42 billion yuan, an increase of 111.61% compared to the previous year[56] - Equity attributable to the parent company was 54.22 billion yuan, up 108.02% year-on-year[56] - Revenue for 2022 reached 61.66 billion yuan, a year-on-year increase of 287.97%[85] - Net profit attributable to the parent company was 30.45 billion yuan, up 312.26% year-on-year[85] - Overseas sales accounted for 99.14% of total revenue, with foreign exchange gains of 511.65 million yuan[78] - Accounts receivable at the end of the reporting period stood at 253.20 million yuan, with 98.06% within one year[79] - Total assets increased by 111.61% to 69.42 billion yuan by the end of 2022[85] - Equity attributable to the parent company rose by 108.02% to 54.22 billion yuan[85] - Sales expenses surged by 1,500.69% to 493.76 million yuan[86] - Financial expenses decreased by 2,411.41% to -533.59 million yuan, primarily due to foreign exchange gains[86] - Revenue from the in vitro diagnostics industry reached 6.165 billion yuan, a year-on-year increase of 287.97%, with a gross margin of 74.78%, an increase of 9.34 percentage points[175] - Revenue from infectious disease testing products was 5.851 billion yuan, a year-on-year increase of 334.60%, with a gross margin of 76.88%, an increase of 7.75 percentage points[175] - Revenue from the North American market was 4.611 billion yuan, a year-on-year increase of 503.09%, with a gross margin of 78.02%, an increase of 9.08 percentage points[176] - Revenue from the ODM sales model was 5.017 billion yuan, a year-on-year increase of 1,524.85%, with a gross margin of 77.14%, an increase of 12.16 percentage points[176] - Production volume of diagnostic reagents reached 85,996.95 thousand units, a year-on-year increase of 186.85%, while sales volume was 77,539.86 thousand units, a year-on-year increase of 173.79%[177] - Direct material costs for the in vitro diagnostics industry were 984.12 million yuan, accounting for 63.29% of total costs, a year-on-year increase of 132.73%[180] - Direct labor costs for the in vitro diagnostics industry were 429.67 million yuan, accounting for 27.63% of total costs, a year-on-year increase of 396.76%[180] - Sales expenses increased by 1,500.69% to 493,759,585.28 yuan due to increased personnel bonuses and promotion expenses[190] - R&D expenses increased by 367.57% to 329,074,506.45 yuan due to continued investment in new product and technology platform development[190] - Net cash flow from operating activities increased by 453.79% to 3,743,278,071.62 yuan due to performance growth[192] - Net cash flow from investing activities decreased by 1,113.13% to -3,614,291,753.32 yuan due to increased fixed asset investment and financial product investments[192] - Trading financial assets increased by 99.99% to 1,405,975,108.31 yuan, accounting for 20.25% of total assets, due to increased bank wealth management investments[194] - Other current assets increased by 30.19% to 2,095,408,384.90 yuan, mainly due to increased bank deposits and time deposit business[195] - Fixed assets increased by 4.9% to 339,937,052.68 yuan, driven by higher investments in equipment and factory buildings[195] - Construction in progress rose by 1.32% to 91,421,013.58 yuan, attributed to increased investment in fundraising projects[195] - Lease assets increased by 0.65% to 44,809,541.95 yuan due to the expansion of leased factory space[195] - Intangible assets grew by 0.60% to 41,586,011.03 yuan, mainly from land payments and software system investments[195] - Deferred tax assets surged by 2.09% to 145,301,308.85 yuan, driven by inventory depreciation and fixed asset impairment provisions[195] - Short-term borrowings increased by 0.13% to 2,000,000 yuan, related to bank loans for company acquisitions[195] - Accounts payable rose by 57.01% to 868,209,160.64 yuan, reflecting higher order volumes[195] - Contract liabilities decreased by 208.65% to 32,248,087.64 yuan, due to a decline in sales and prepayments[195] - Investment amount for the reporting period was 24,200,000 yuan[200] Research and Development - Research and development expenses increased by 22.7% to RMB 450 million, accounting for 13% of total revenue[35] - The company successfully obtained FDA 510(k) clearance for 3 new IVD products during the reporting period[34] - The company launched 12 new POCT products in 2022, contributing to a 15% increase in product portfolio[35] - R&D expenditure as a percentage of revenue increased by 0.91 percentage points year-on-year to 5.34%, indicating continued investment in innovation[43] - The company obtained 9 new domestic medical device registrations/filings in 2022[57] - The company obtained 1 new international medical device registration in Canada in 2022[57] - The company's R&D investment in 2022 increased by 367.57% year-on-year, reaching a total of 329,074,506.45 yuan[60] - The proportion of R&D investment to operating income in 2022 was 5.34%, an increase of 0.91 percentage points compared to the previous year[60] - The significant increase in R&D investment is attributed to the company's continued focus on new product development, registration, and new technology platform projects[61] - The company obtained multiple certifications for COVID-19 antigen nasal test kits in Australia, with a total of 372,335 units certified[58] - The company received EU CE certification for its HIV rapid test device, COVID-19 & Influenza A/B antigen nasal test kit, and COVID-19 antigen saliva test kit[58] - The company obtained ANVISA certification in Brazil for RSV test, Norovirus test, H.pylori Ag test, and H.pylori Ab test kit[58] - The company received EU CE certification for Monkeypox antibody and antigen rapid test devices, as well as Monkeypox nucleic acid detection kits[58] - The company obtained ANVISA certification in Brazil for Strep A test, Malaria test, FOB test, Flu A/B rapid test, Gonorrhea rapid test, Zika rapid test, and HbsAg rapid test[59] - The company received certifications in Guatemala for Rotavirus and Adenovirus combined test, Dengue virus test, H.pylori test, Syphilis test, and Multidrug test panels[59] - The company has 60 R&D projects, with 40 completed and the rest in various stages of development, focusing on areas such as POCT clinical testing, food safety testing, and judicial testing[63] - The company's R&D personnel increased to 286, accounting for 30.11% of the total workforce, with a total R&D salary of 4764.67 million yuan[64] - The company's core competitiveness lies in its technological innovation, with a focus on POCT reagents and instruments, covering eight major fields including drug detection, infectious disease detection, and chronic disease detection[66] - The company has a strong capability in core biological raw material preparation, with 37 antigen and antibody raw material R&D projects, of which 25 have been completed[67] - The company's R&D and core technology advantages include a diverse team of professionals and a dual-driven development model focusing on market demand and technological innovation[68] - The company has a comprehensive product line and efficient product iteration, with a focus on infectious disease detection products and a complete technology platform[69] - The company emphasizes quality and brand advantages, adhering to strict quality control and building a strong brand presence both domestically and internationally[70] - The company's core management team has extensive experience and expertise in the POCT industry, driving product differentiation and technological innovation[71] - The company has established six major technology platforms, including a new biopharmaceutical platform, and has formed an integrated industrial chain layout of raw materials, reagents, and instruments[144] - The company has developed a series of "pen-type" products for respiratory infectious disease detection, including COVID-19, influenza A/B, and multi-plex detection, and has expanded this technology to other global infectious diseases such as HIV, dengue, and malaria[144] - The company has launched a comprehensive home health management solution, covering prevention, early screening, and post-treatment monitoring, with products for blood glucose, lipids, hemoglobin, myocardial health, and female physiological health[145] - The company has obtained 102 new authorized patents, including 3 invention patents and 11 utility model patents, and has accumulated a total of 212 authorized patents[145] - The company has received 37 new certifications, including 28 international certifications, bringing the total number of certifications to 175[145] - The company has established an industrial investment fund, Hangzhou Chuanxu Equity Investment Partnership, focusing on early-stage and growth-stage projects in pharmaceuticals, healthcare, and biopharmaceuticals[146] - The company has acquired 100% equity of Hunan Tianzong and Hunan Dayou, and established overseas subsidiaries in Singapore and the United States to support its healthcare industry development[146] - The company has set up a medical testing laboratory to conduct molecular diagnostic projects, including respiratory pathogen gene detection, infectious virus detection, and non-invasive prenatal screening[146] - The company has collaborated with universities such as Zhejiang Gongshang University, Zhejiang University City College, and Zhejiang University to establish research centers and introduce advanced scientific talent[147] - The company has strengthened the progress control of two provincial key projects: the fully automated testing integrated machine and ultra-high sensitivity Listeria monocytogenes detection kit development project, and the research and application project of multiple non-crosstalk fluorescent encoding microspheres for bio-liquid chips[148] - The company has established local companies in Singapore and the United States, and set up research and sales centers in key domestic cities including Beijing, Nanjing, Chengdu, Changsha, and Wuxi, focusing on domestic network layout[150] - The company has completed the integration of the entire upstream and downstream supply chain, achieving three self-controllable aspects: core raw materials, key equipment, and key technologies[151] - The company has optimized the cost structure and accelerated the pace of machine replacement, developing and testing the fourth-generation equipment of intelligent manufacturing production lines[151] - The company has successfully launched the ERP system, initiating the digital management upgrade and building a unified enterprise resource control platform[152] - The company has mastered gene engineering recombinant antigen technology, synthetic antigen technology, polyclonal antibody preparation technology, and monoclonal antibody preparation technology, achieving partial self-supply of nearly 100 products required antigens and antibodies, accounting for more than half of the company's biological raw material demand[158] - The company has formed a complete research, development, and innovation system, continuously iterating and improving products based on market and customer needs, and actively researching industry development trends to develop new products with foresight[163] Market and Industry Analysis - International sales accounted for 45% of total revenue, with significant growth in European and North American markets[35] - The company completed the acquisition of Hunan Tianzong Yijun Biotech, expanding its presence in the Chinese domestic market[34] - The company faces risks from intensified competition and potential market share loss[75] - New EU IVDR regulations may impact the company's ODM business in Europe[82] - The global IVD market in 2022 was valued at 127.4 billion USD, with the POCT segment (excluding diabetes) accounting for 28.7 billion USD, or 22.5% of the market[93] - The company plans to expand production capacity, upgrade existing products, and enhance automation to improve efficiency and scale[96] - The company aims to increase its market share

2022 年年度报告 公司代码：688075 公司简称：安旭生物 杭州安旭生物科技股份有限公司 2022 年年度报告 1 / 218 2022 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生 重大不利影响的风险因素，敬请投资者注意投资风险。 四、 公司全体董事出席董事会会议。 (一) 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 五、 公司负责人凌世生、主管会计工作负责人康敏及会计机构负责人（会计主管人员）林晓声明： 保证年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司第二届董事会第八次会议审议通过了2022年度利润分配及资本公积转增股本预案如下： 公司拟向全体股东每 10 股派发现金红利 50 元（含税）。截至 2022 年 12 ...

2023 年第一季度报告 证券代码：688075 证券简称：安旭生物 杭州安旭生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是√否 一、 主要财务数据 (一)主要会计数据和财务指标 | | | | 单位：元 | 币种：人民币 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | | 本报告期比上年同 | | | | | | 期增减变动幅度(%) | | | 营业收入 | | 121,477,537.33 | | -97.78 | | 归属于上市公司股东的净利润 | | 50,831,559.77 | | -98.10 | | 归属于上市 ...

杭州安旭生物科技股份有限公司 投资者关系活动记录表 证券简称：安旭生物 证券代码：688075 编号：2022-004 | --- | --- | --- | |-----------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 □媒体采访 | | 投资者关系 活动类别 | □业绩说明会 | □新闻发布会 □路演活动 | | | 现场参观 | □其他（电话会议） | | | 国信证券 超、王文韬 | 李伟波、苏于、许瑶佳、马彩利、方丹、毛静、劳世 | | | 君弘资产 | 郑确、苏颖 君颐资产 娄志刚 | | 参与单位名 | 盛元资本 | 许柳、沈萍 礼翰投资 罗杭婷 | | | 长添资产 童鸿 | 正帛资产 楼浩 | | | 敦敏资产 ...

2022 年第三季度报告 证券代码：688075 证券简称：安旭生物 杭州安旭生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 196,648,169.86 | 4.62 | 6,126,614,488.82 | 798.35 ...

2022 年半年度报告 公司代码：688075 公司简称：安旭生物 杭州安旭生物科技股份有限公司 2022 年半年度报告 二〇二二年八月 1 / 169 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"五、风险因素"中说明了可能对公司产生重大 不利影响的风险因素，敬请投资者注意投资风险。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人凌世生、主管会计工作负责人吴娅鸿及会计机构负责人（会计主管人员）林晓声 明：保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、经营计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意投资风险。 九、是否存在被控股股东及其关联方非经营 ...

重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 2021 年年度报告 公司代码：688075 公司简称：安旭生物 杭州安旭生物科技股份有限公司 2021 年年度报告 二〇二二年四月 1 / 226 2021 年年度报告 □是 √否 三、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生 重大不利影响的风险因素，敬请投资者注意投资风险。 四、 公司全体董事出席董事会会议。 五、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人凌世生、主管会计工作负责人吴娅鸿及会计机构负责人（会计主管人员）林晓声 明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司第一届董事会第二十二次会议审议通过了公司2021年度利润分配方案如下：公司拟向全 体股东每10股派发现金红利38.80元（含税）。截至2021年12月 ...

2022 年第一季度报告 证券代码：688075 证券简称：安旭生物 杭州安旭生物科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 注：上年同期经营活动产生的现金流量净额为-3,141,561.96 元，故不计算本报告期比上年同期 增减变动幅度。 (二)非经常性损益项目和金额 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | 8,591.26 | | | 计入当期损益的政府补助，但与公 | 46,901.92 | | | 司正常经营业务密切相关，符合国 | | | | 家政策规定、按照一定标准 ...